Novel agents in mantle cell lymphoma

References

• Zhou Y, Wang H, Fang W. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113:791–798.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumours of haematopoietic and lymphoid tissues. France: International Agency for Research on Cancer (IARC). 2008.
   Google Scholar
• Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7:750–762.
   PubMed Web of Science ®Google Scholar
• Sherr CJ. G1 phase progression: cycling on cue. Cell. 1994;79:551–554.
   PubMed Web of Science ®Google Scholar
• Jares P, Colomer D, Campo E. Review series. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012 Oct;122(10):3416-3423.
   Google Scholar
• Pérez-Galán P, Dreyling M, Wiestner A, et al. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117:26–38.
   PubMed Web of Science ®Google Scholar
• Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94:1555–1562.
   PubMed Web of Science ®Google Scholar
• Vegliante MC, Palomero J, Pérez-Galán P, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013;121:2175–2185.
   PubMed Web of Science ®Google Scholar
• Nordström L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study. Br J Haematol. 2014;166:98–108.
   PubMed Web of Science ®Google Scholar
• Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72:5307–5316.
   PubMed Web of Science ®Google Scholar
• Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70:1408–1418.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad LE, L F, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150:200–208.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang M, Romaguera J. Current regimens and novel agents for mantle cell lymphoma. Br J Haematol. 2014;167:3–18.
   PubMed Web of Science ®Google Scholar
• Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood. 2013;121:48–53.
   PubMed Web of Science ®Google Scholar
• Eve HE, Furtado MV, Hamon MD, et al. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol. 2009;27:e189–e190; author reply e191.
   PubMed Web of Science ®Google Scholar
• Campo E, Rule S. Mantle cell lymphoma: evolving management strategies. Blood J. 2015;125:48–56.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ferrero S, Hermine O How to manage mantle cell lymphoma. Leukemia. [Internet]. 2014;28:2117–2130. DOI:10.1038/leu.2014.171
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175:410–418.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687–2693.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Addition of highdose cytarabine to immunochemotherapy before autologous stemcell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, openlabel, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 2016;6736:1–11.
   Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23:7013–7023.
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Ilariucci F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol. 2012;156:346–353.
   PubMed Web of Science ®Google Scholar
• Bernstein SH, Epner E, Unger JM, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol. 2013;24:1587–1593.
   PubMed Web of Science ®Google Scholar
• Rule S, Smith P, Johnson PWM, et al. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK national cancer research institute trial. Haematologica. 2016;101:235–240.
   PubMed Web of Science ®Google Scholar
• Lens G. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results o. J Clin Oncol. 2005;23:1984–1992.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520–531.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Van Der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. [Internet]. 2014 [cited 2014 Dec 29];123:2944–2952. Available from. http://www.ncbi.nlm.nih.gov/pubmed/24591201
   PubMed Web of Science ®Google Scholar
• Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31:1442–1449.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Knauf W, Goerner M, et al. Two years rituximab vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomised, multicenter phase II study (a subgroup of the StiL NHL7-2008 MAINTAIN. J Clin Oncol. 34, 2016; (suppl;abstr7503).
   Google Scholar
• Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:3383–3389.
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Phase CF. 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 2008;113:2734–2741.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Geyer SM, Kurtin P, et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma. 2008;49:1074–1080.
   PubMed Web of Science ®Google Scholar
• Adams J, The proteasome: a suitable antineoplastic target. Nat Rev Cancer. [Internet]. 2004;4:349–360.DOI: 10.1038/nrc1361
   PubMed Web of Science ®Google Scholar
• Glotzer M, Murray AW, Kirschner MW. Cyclin is degrated by the ubiquitin pathway. Nature. 1991;349:132–138.
   PubMed Web of Science ®Google Scholar
• Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 1996;56:2649–2654.
   PubMed Web of Science ®Google Scholar
• Palombella VJ, Rando OJ, Goldberg AL, et al. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell. [Internet]. 1994;78:773–785. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-0027980321&partnerID=40&md5=45d01b0d33968139d533b0dce715eb83
   PubMed Web of Science ®Google Scholar
• Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13:5291–5294.
   PubMed Web of Science ®Google Scholar
• Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res. [Internet]2003;9:1145–1154. Available from: www.ncbi.nlm.nih.gov/pubmed/12631620
   PubMed Web of Science ®Google Scholar
• Bross PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res. 2004;10:3954–3964.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420–4427.
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20:520–525.
   PubMed Web of Science ®Google Scholar
• Morrison V A, Jung SH, Johnson J, et al. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB. 50501). Leuk Lymphoma. 2015;56:958–964.
   PubMed Web of Science ®Google Scholar
• Furtado M, Johnson R, Kruger A, et al. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015;168:55–62.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29:690–697.
   PubMed Web of Science ®Google Scholar
• Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. [Internet]. 2015;372:944–953. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25738670
   PubMed Web of Science ®Google Scholar
• Doorduijn JK, Minnema M, Kersten M, et al. Bortezomib maintenance therapy after induction with R-Chop, Ara-C and autologous stem cell transplantation in newly diagnosed MCL patients, results of a multicenter phase II Hovon study. Blood. 2015;126:339–339.
   Web of Science ®Google Scholar
• Chang JE, Li H, Smith MR, et al. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood. 2014;123:1665–1673.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–4874.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676–684.
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. [Internet]. 2011;12:431–440. DOI: 10.1016/S1470-2045(11)70081-X
   PubMed Web of Science ®Google Scholar
• Till BG, Li H, Bernstein SH, et al. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol. 2016;172:208–218.
   PubMed Web of Science ®Google Scholar
• Celgene. Revlimid: highlights of prescribing information reference ID. 2013;3319577.
   Google Scholar
• Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. [Internet]. 2009;2:36. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2736171&tool=pmcentrez&rendertype=abstract
   PubMed Web of Science ®Google Scholar
• Mitsiades N. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. [Internet]. 2002;99:4525–4530. Available from: http://www.bloodjournal.org/content/99/12/4525.abstract
   PubMed Web of Science ®Google Scholar
• Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood. 2015;126:2366–2369.
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. [Internet]. 1999; 163:380–386. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10384139.
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott JB, Todryk SM, et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol. 2002;168:4914–4919.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005;128:192–203.
   PubMed Web of Science ®Google Scholar
• Chang DH, Liu N, Klimek V, et al. Brief report enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006;108:618–621.
   Google Scholar
• Witzig TE, Nowakowski GS, Habermann TM, et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol. 2015;26:1667–1677.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114:4713–4720.
   PubMed Web of Science ®Google Scholar
• Qian Z, Zhang L, Cai Z, et al. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res. [Internet]2011;35:380–386. DOI: 10.1016/j.leukres.2010.09.027
   PubMed Web of Science ®Google Scholar
• Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009;84:553–559.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4952–4957.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:5404–5409.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22:1622–1627.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013;24:2892–2897.
   PubMed Web of Science ®Google Scholar
• Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol. 2012;159:154–163.
   PubMed Web of Science ®Google Scholar
• Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688–3695.
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. [Internet]. 2012; 13:716–723. DOI: 10.1016/S1470-2045(12)70200-0.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. [Internet]. 2015;373:1835–1844. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26535512
   PubMed Web of Science ®Google Scholar
• Flinn IW, Mainwaring M, Peacock N, et al. Rituximab, lenalidomide, and bortezomib in the first-line or second-line treatment of patients with mantle cell lymphoma a phase I/II trial. Blood. 2012;120(21):2748.
   Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140:36–45.
   PubMed Web of Science ®Google Scholar
• Rudelius M, Pittaluga S, Pham -TH-T, et al. Constitutive activation of AKT contributes to the pathogenesis and survival of blastoid variants of mantle cell lymphoma. Blood. [Internet]. 2006;108:1668–1676. Available from: http://www.bloodjournal.org/content/106/11/1908.abstract
   PubMed Web of Science ®Google Scholar
• Witzig TE, Kaufmann SH. Inhibition of the Phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options in Oncol. 2006;7:285.
   PubMedGoogle Scholar
• Bjornsti M-A, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335–348.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347–5356.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. [Internet]. 2009;27:3822–3829. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2008.20.7977
   PubMed Web of Science ®Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770–778.
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. [Internet]. 2010;107:13075–13080. [cited 2014 Dec 15. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2919935&tool=pmcentrez&rendertype=abstract
   PubMed Web of Science ®Google Scholar
• Buggy JJ. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int. Rev. Immunol. 2012;32:119–132.
   Web of Science ®Google Scholar
• Dal Porto JM, Gauld SB, Merrell KT, et al. B cell antigen receptor signaling 101. Mol Immunol. 2004;41:599–613.
   PubMed Web of Science ®Google Scholar
• Maas A, Hendriks RW. Role of Bruton’s tyrosine kinase in B cell development. Dev Immunol. 2001;8:171–181.
   PubMedGoogle Scholar
• Bruton O. Agammaglobulinemia. Pediatrics. 1952;9:722–728.
   PubMed Web of Science ®Google Scholar
• Tsukada S, Rawlings DJ, Witte ON. Role of Bruton’s tyrosine kinase in immunodeficiency. Curr Opin Immunol. 1994;6:623–630.
   PubMed Web of Science ®Google Scholar
• Satterthwaite AB, Witte ON, Witte O. The role of Bruton ’ s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000;175:120–127.
   PubMed Web of Science ®Google Scholar
• Ponader S. Burger J A. Bruton’s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. [Internet]. 2014; 32: 1830–1839. [cited 2014 Dec 29 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24778403
   PubMed Web of Science ®Google Scholar
• Chang BY, Francesco M, Mfm DR, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. [Internet]. 2013;122:2412–2424. [cited 2014 Dec 21. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3790509&tool=pmcentrez&rendertype=abstract
   PubMed Web of Science ®Google Scholar
• Rushworth SA, Bowles KM, Barrera LN, et al. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cell Signal. 2013;25:106–112.
   PubMed Web of Science ®Google Scholar
• Herman SEM, Mustafa RZ. Gyamfi J A, et al. Ibrutinib inhibits BCR and Nf-Κb signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123:3286–3295.
   PubMed Web of Science ®Google Scholar
• Zheng X, Ding N, Song Y, et al. Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment. Cancer Cell Int. [Internet]. 2014;14:32. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3984027&tool=pmcentrez&rendertype=abstract
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. [Internet]. 2006;132:303–316. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16409295
   PubMed Web of Science ®Google Scholar
• Bernard S, Danglade D, Gardano L, et al. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int J Cancer. [Internet]. 2014;0:1–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25388373
   Google Scholar
• Kurtova AV, Tamayo AT, Ford RJ, et al. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113:4604–4613.
   PubMed Web of Science ®Google Scholar
• Psyrri A, Papageorgiou S, Liakata E, et al. Phosphatidylinositol 3ʹ-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res. [Internet]. 2009;15:5724–5732. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=19723646%5Cnhttp://tq5wt9yw2k.search.serialssolutions.com/?sid=OVID:Ovid+MEDLINE(R)+%3C2008+to+April+Week+3+2012%3E&genre=article&id=pmid:19723646&id=doi:&issn=1078-0432&volume=15&issu
   PubMed Web of Science ®Google Scholar
• Baran-Marszak F, Boukhiar M, Harel S, et al. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica. [Internet]. 2010;95:1865–1872. Available from: http://www.haematologica.org/cgi/content/abstract/95/11/1865%5Cnhttp://www.haematologica.org/cgi/content/abstract/95/11/1865?etoc%5Cnhttp://www.haematologica.org/cgi/reprint/95/11/1865.pdf
   PubMed Web of Science ®Google Scholar
• Cinar M, Hamedani F, Mo Z, et al. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis. Leuk Res. [Internet]. 2013;37:1271–1277. DOI: 10.1016/j.leukres.2013.07.028
   PubMed Web of Science ®Google Scholar
• Burger JA, Buggy JJ. Emerging drug profiles; Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765). Leuk Lymphoma. 2013;54:2385–2391.
   PubMed Web of Science ®Google Scholar
• Ou Z. Single agent Bruton’s tyrosine kinase (Btk) inhibitor and single agent carfilzomib induce cell apoptosis, arrest cell growth and down-regulate NFkb activity in mantle cell lymphoma. ASH Annu Meet.  November 18, 2011; 118(21).
   Google Scholar
• Pan Z, Scheerens H, Li S-J, et al. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. Chem Med Chem. [Internet]. 2007;2:58–61. [cited 2014 Oct 24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17154430
   Web of Science ®Google Scholar
• Ponada S, Balasubramanian S, L V P, et al. Activity of Bruton’s tyrosine kinase (Btk) Inhibitor PCI-32765 in mantle cell lymphoma (MCL) identifies Btk as a novel therapeutic target. ASH Annu Meet. 3688. November 18, 2011; 118(21).
   Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. [Internet]. 2013;369:507–516. [cited 2014 Sep 15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23782157
   PubMed Web of Science ®Google Scholar
• Wang ML. Blum K A, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739–746.
   Google Scholar
• Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17:48–56.
   PubMed Web of Science ®Google Scholar
• Maddocks K, Christian B, Jaglowski S, et al. A phase 1 /1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;125:242–249.
   PubMed Web of Science ®Google Scholar
• Wang M, Hagemeister F, Westin JR, et al. Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a phase II clinical trial. ASH Annu Meet. 2014;124(21). Oral. Session 624.
   Google Scholar
• Wang ML, Thirumurthi S, Chuang HH, et al. Chemotherapy-free induction with ibrutinib-rituximab followed by shortened cycles of chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma patients: a phase II clinical trial. Blood. 2016;128(22):147.
   PubMed Web of Science ®Google Scholar
• Maddocks K, Christian B, Jaglowski S, et al. Clinical Trials and Observations: A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;125:242–248.
   Google Scholar
• Mfm DR, Kuil A. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood. 2015;125:2306–2309.
   PubMed Web of Science ®Google Scholar
• Zhao X, Bodo J, Sun D. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2015;168:757–768.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26:1175–1179.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Lozanski G, et al. Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: a single-center experience of 267 patients. ASCO Meet Abstr. 2014;32:7010.
   Google Scholar
• Woyach JA, Furman RR, Liu T-M, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. [Internet]. 2014;370:2286–2294. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24869598
   PubMed Web of Science ®Google Scholar
• Balasubramanian S, Schaffer M, Deraedt W. Mutational analysis of patients with primary resistance to single-agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL). ASH Annu Meet. 2014;124(21).
   Google Scholar
• Lenz G, Balasubramanian S, Goldberg JD, et al. Sequence variants in patients with primary and aquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial. Haematologica. June 2016: 135195.
   Google Scholar
• Ma J, Lu P, Guo A, et al. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. Br J Haematol. [Internet]. 2014. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24957109
   Web of Science ®Google Scholar
• Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175-1179.
   PubMed Web of Science ®Google Scholar
• Levade M, David E, Laurent P, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2015;124:3991–3996.
   Web of Science ®Google Scholar
• Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. [Internet]. 2014; 1–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25138588.
   Web of Science ®Google Scholar
• McMullen JR, Boey EJH. Correspondence to the editor: ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac. Blood. 2014;124:3829–3831.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2015;123:3398–3406.
   Web of Science ®Google Scholar
• Zydelig FDA required REMS safety information. 2014.
   Google Scholar
• Burger JA. Bruton’s tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014;9(1):44-49.
   PubMed Web of Science ®Google Scholar
• Walter HS, Rule SA, Dyer MJS, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127:411–419.
   PubMed Web of Science ®Google Scholar
• Rajasekeran N, Sadaram M, Hebb J, et al. Three BTK-specific inhibitors, in contrast to ibrutinib, do not antagonise rituximab-dependent NK-Cell mediated cytotoxicity. ASH Annu Meet. 2014;124(21):625.
   Google Scholar
• Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. [Internet]. 2015; 151207133057003. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1509981%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/26641137%5Cnhttp://www.nejm.org/doi/abs/10.1056/NEJMoa1509981.
   Web of Science ®Google Scholar
• Covey T, Barf T, Gulrajani M, et al. Abstract 2596: ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Res. [Internet]. 2015;75:2596LP–2596. Available from: http://cancerres.aacrjournals.org/content/75/15_Supplement/2596.abstract
   Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. [Internet]. 2013;19:202–208. Available from: http://dx.doi.org/10.1038/nm.3048%5Cnhttp://www.nature.com/doifinder/10.1038/nm.3048.
   PubMed Web of Science ®Google Scholar
• Korz C, Pscherer A, Benner A, et al. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood. 2002;99:4554–4561.
   PubMed Web of Science ®Google Scholar
• Balakrishnan K, Gandhi V. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs. 2013;31:1384–1394.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Connor OAO, Czuczman MS, et al. Safety, pharmacokinetics, pharcodynamics, and activity of navitoclax, a targeted high affinity inhibitor of BCL-2, in lymphoid malignancies. Lancet Oncol. 2011;11:1149–1159.
   Web of Science ®Google Scholar
• Schoenwaelder SM, Jarman KE, Gardiner EE, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118:1663–1674.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. [Internet]. 2016;374:311–322. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1513257
   PubMed Web of Science ®Google Scholar
• Chiron D, Dousset C, Brosseau C, et al. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget. 2015;6:8750–8759.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Gerecitano JF, Kahl BS, et al. The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients. Davids MS, editor. Blood. [Internet]. 2013;122:1789LP–1789. Available from: http://www.bloodjournal.org/content/122/21/1789.abstract
   Google Scholar
• Davids MS, Roberts AW, Anderson MA, et al. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study. Blood. [Internet]. 2015;120:304LP–304. Available from: http://www.bloodjournal.org/content/120/21/304.abstract
   Google Scholar
• Medina DJ, Goodell L, Glod J, et al. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways. Haematologica. [Internet]. 2012;97:1255–1263. [cited 2014 Dec 29. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3409825&tool=pmcentrez&rendertype=abstract
   PubMed Web of Science ®Google Scholar
• Armand P. Review article. Immune checkpoint blockade in hematologic malignancies. Blood. 2015;125:3393–3401.
   PubMed Web of Science ®Google Scholar
• Hodi S, O’Day S, McDermott D, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory hodgkin’s lymphoma. N Engl J Med. 2015;372:311–319.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab (MDX-010), an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B- cell non-Hodgkin lymphoma. Clin Cancer Res. 2010;15:6446–6453.
   Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood. [Internet]. 2014;124:291LP–291. Available from: http://www.bloodjournal.org/content/124/21/291.abstract
   Web of Science ®Google Scholar